Product

abatacept

Name

ORENCIA

INN Name

abatacept

FDA Approved

Yes

2 clinical trials

1 organization

2 indications

1 document

Indication

CTLA4 Haploinsufficiency

Indication

Rheumatoid Arthritis

Clinical trial

Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

Status: Withdrawn, Estimated PCD: 2023-11-30

Clinical trial

Comparative Effectiveness of New Initiators of Tofacitinib and Other Biologic/Targeted Synthetic DMARDs in Patients With Rheumatoid Arthritis

Status: Active (not recruiting), Estimated PCD: 2024-07-15

Document

DailyMed Label: ORENCIA

Organization

E.R. Squibb & Sons, L.L.C.